Company Filing History:
Years Active: 2021-2024
Title: Elaine M Hurt: Innovator in Monoclonal Antibody-Drug Conjugates
Introduction
Elaine M Hurt is a prominent inventor based in Gaithersburg, MD (US). She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibody-drug conjugates. With a total of four patents to her name, Elaine has established herself as a key figure in her area of expertise.
Latest Patents
One of her latest patents is focused on a BCMA monoclonal antibody-drug conjugate. This invention is directed towards an antibody-drug conjugate (ADC) that comprises a monoclonal antibody, or an antigen-binding fragment thereof, specifically targeting B-cell maturation antigen (BCMA) conjugated to a cytotoxin. The patent also outlines compositions that include the antibody-drug conjugate and methods for effectively killing multiple myeloma cells, including multiple myeloma stem cells, that express BCMA by utilizing the ADC. Another significant patent involves antibodies directed against GDF-15. This disclosure pertains to human GDF-15-binding antibodies and their antigen-binding fragments, which can be utilized for detecting human GDF-15 and in methods for treating cancer or body weight loss, including cachexia, associated with the over-expression of human GDF-15.
Career Highlights
Elaine M Hurt is currently associated with Medimmune Limited, where she continues to innovate and contribute to advancements in medical science. Her work has been instrumental in developing therapies that address critical health issues.
Collaborations
Elaine has collaborated with notable coworkers, including Krista Lynne Kinneer and Reena Varkey, enhancing the impact of her research through teamwork and shared expertise.
Conclusion
Elaine M Hurt's contributions to the field of biotechnology, particularly through her patents on monoclonal antibody-drug conjugates, highlight her role as an influential inventor. Her work continues to pave the way for innovative treatments in cancer therapy and beyond.